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Intermittent positive-pressure breathing (IPPB) is a mode of administering aerosolised drugs to asthmatic patients (Petty, 1974) . It has been argued that IPPB offers no advantage over quiet breathing as an aerosol administration mode, and recent work by Dolovich et al (1977) Eight subjects were regularly using inhaled salbutamol and beclomethasone diproprionate aerosols; two of them were also taking regular oral theophylline. Each subject was familiar with the use of the IPPB apparatus (Bird Mark 10 respirator). All study days were started after a 15-minute rest period, at the same time of day for each subject. When possible studies were conducted on consecutive days, provided that the baseline FEV1 was within -+15% of the first day's value. No subject received inhaled bronchodilator for eight hours before each study day, the two taking oral theophylline omitted this drug for 24 hours before each study day, but those taking inhaled beclomethasone diproprionate continued this medication in the usual dose. None was exposed to a relevant allergen, other than housedust, for at least four weeks before the study.
Ventilatory function was determined by measuring FEV1, mean forced expiratory flow rate over the middle half of the forced vital capacity (FEV25-75%), and forced vital capacity (FVC) from the best of three spirograms recorded on a bellows spirometer (Vitalograph). All volumes were measured at BTPS. Ventilatory function, pulse rate, and blood pressure were measured just before drug administration and at 30, 60, 90, 120, 180, and 240 minutes after.
After baseline measurements the subjects received an aerosol produced from 5 ml of saline containing either 0, 0 25, 0 50, 1 0, 2-5, or 5 mg of salbutamol in a double-blind fashion with randomised order of administration.
An ultrasonic generator (Monaghan 670B) was used to produce aerosol particles of 3 9 p.m aerodynamic mass median diameter (g 1 6). The same Bird Mark 10 respirator driven by 50 pounds per square inch pressure (344-7 kPa) of compressed air was used to deliver the aerosol to each subject (fig 1) . The dead space between the subject's mouth and the generator was 25 ml. The same respirator settings were used for each subject. On average it took 10 (range 9 to 12 5) minutes for the ultrasonic generator to cease producing visible aerosol. When no further aerosol was being produced this was called zero time. The range of expiratory volumes, measured with a Wright respirometer, was 10 to 2-7 1, and the breathing frequency ranged between 11 and 17 breaths a minute.
RADIOTRACER STUDY IN NORMALS
We used the radiotracer method described by One-way valve Ruffin et al (1978a) to measure the amount of aerosol deposited in the airways, stomach, and oropharynx of four healthy subjects-two men and two women (age range 22-33). Their baseline FEV1 ranged from 98 to 112% of the predicted value. The aerosols for inhalation were produced by an ultrasonic generator and a Bird nebuliser and delivered under the same conditions as in the first method. To enable sufficient data points to be obtained each subject inhaled the aerosol at varying tidal volumes between 1 0 and 4-0 1 in separate experiments. The radioactivity deposited in each subject was calculated as described by Ruffin et al, (1978a) . "'Tc HSA was used as the radiotracer, so that absorption of the radioactivity in the 10-minute breathing period was not significant in contrast to "mTc pertechnetate which has an effective lung half-life of about 15 minutes (Ruffin et al, 1978a) . On the basis of clearance studies in normal subjects, the amount removed from the lungs during the 10-minute inhalation period is less than 1% of the total airway dose (Ruffin et al, 1978b ).
Statistical analysis was performed by two-way analysis of variance with a multiple range comparison test (Sokal and Rohlf, 1969) and linear regression analysis by the method of least squares (Snedecor and Cochran, 1956 provement in FEV1 compared with placebo for the four hours after drug administration, as did the 2-5 mg dose (P<0 05) (fig 2) . The 1 mg and 0 25 mg doses produced significant improvement in FEV1 compared with placebo, but not for the entire fourhour study. The response to 0O5 mg of salbutamol did not reach statistical significance (P>0-05). There was no significant difference between the FEV1 increase produced by the 5 mg, 2-5 mg, and I mg doses of salbutamol until the 240 minute reading when the FEV1 increase produced by the 5 mg dose was greater than that by the 1 mg dose (P>0 05) (fig 2) . Similar trends were observed with the increases in FEV25-75% and FVC. The only significant change in blood pressure or pulse rate occurred at 30 minutes when 5 mg of salbutamol caused a mean 8 2 mmHg increase in systolic blood pressure (P<0-05). Three subjects complained of tremor and one felt apprehensive after the 5 mg salbutamol dose, one of these subjects also had tremor after the 2 5 mg salbutamol dose, while another complained of transient facial paresthesiae after each salbutamol dose except the 0 5 mg dose.
RADIOTRACER STUDY IN NORMAL SUBJECTS
The study with four normal subjects showed an inverse relationship between the percentage of the nebuliser dose being deposited in the lungs and the depth of breathing (fig 3) . The correlation coefficient was -0-73 for the Monaghan nebuliser (P< 0 05) and -0 51 for the Bird micronebuliser (P<0-2) for the relation between tidal volume and percentage deposition in the lungs. Figure 1 shows a composite set of scintiphotos demonstrating the distribution of radioactivity after the generator was no longer producing visible aerosol. For the Monaghan nebuliser studies the mean (+SE) recovery rat 88 5% (-+-29) and for th studies 87 7% (+-31). (Shenfield et al, 1973; 1974) measurements of bronchodilator dose by radiotracer techniques have been made. The 95% confidence limits for the relationship between tidal volume and percentage lung deposition in normal subjects (fig 3) for the Monaghan nebuliser were, at 1 1 tidal volume, a range of 5-2 to 9-8% lung deposition. Although increasing the number of subjects is likely to decrease the 95% confidence range limits, our experimental evidence contradicts the assumption of equivalent aerosol dose delivered to subjects via IPPB, as has been suggested by Choo-Kang et al (1970) .
Previous studies of the bronchodilator effect of salbutamol administered by IPPB have: (1) (Spitzer et al, 1972) .
With the possible variation in effective bronchodilator dose (or airway bronchodilator dose) in mind, the present study has shown that using a 5 mg dose of salbutamol in the generator achieves a longer period of bronchodilatation than the 1 mg dose. The longer duration of effect is to be expected with a large dose, since the local drug concentration will be at effective levels for a longer period than with a smaller dose. It is important to note that a dose-related increase in FEV1 was observed in this study. The lack of statistical significance of this trend is probably due to the small number of subjects. The larger dose is accompanied by an increasing incidence of side effects, however, and for most purposes in mild to moderate asthma the smaller dose would appear to be more appropriate.
The data obtained with the radiotracer technique suggests that the percentage lung dose is similar when using either a Monaghan ultrasonic nebuliser or a Bird micronebuliser. Asmundsson et al (1973) used a similar radiotracer technique to measure the absolute deposition of saline in the lungs and found no significant difference between an ultrasonic nebuliser (1%) and the Bird micronebuliser with IPPB (2%). In their four subjects studied with IPPB Asmundsson et al (1973) noted that the amount of deposition of saline in the lungs was inversely proportional to the tidal volume (range 1-2-31 1). Shenfield et al (1973) found that the total dose of tritiated salbutamol via IPPB received by five subjects was 15-20% of the nebuliser dose, but tidal volume during the IPPB breathing was not measured. Thus there is some discrepancy between the results of Asmundsson et al (1973) and Shenfield et al (1973 (Davies, 1975) then about 20 ,ug of salbutamol in the lung from two puffs of an MDI gives near maximum bronchodilatation (Minette, 1971 
